ChiCTR2300074667 版本V1.1 版本创建时间2023/12/28 23:34:21 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300074667 

最近更新日期:

Date of Last Refreshed on:

2023-08-11 16:47:44 

注册时间:

Date of Registration:

2023-08-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

诱导性视力下降对立体视觉影响的研究

Public title:

Study on the Influence of Induced Vision Loss on Stereoscopic Vision

注册题目简写:

English Acronym:

研究课题的正式科学名称:

诱导性视力下降对立体视觉影响的研究

Scientific title:

Study on the Influence of Induced Vision Loss on Stereoscopic Vision

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

刘璐 

研究负责人:

吴荒 

Applicant:

Liu Lu 

Study leader:

Wu Huang 

申请注册联系人电话:

Applicant telephone:

+86 188 4416 3776

研究负责人电话:

Study leader's
telephone:

+86 178 0807 0379

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1847082401@qq.com

研究负责人电子邮件:

Study leader's E-mail:

wuhuang@jlu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国吉林省长春市南关区自强街218号

研究负责人通讯地址:

中国吉林省长春市南关区自强街218号

Applicant address:

218 Ziqiang Street, Nanguan District, Changchun, Jilin, China.

Study leader's address:

218 Ziqiang Street, Nanguan District, Changchun, Jilin, China.

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

吉林大学第二医院

Applicant's institution:

The Second Hospital of Jilin University

研究负责人所在单位:

吉林大学第二医院

Affiliation of the Leader:

The Second Hospital of Jilin University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2023)年审第(130)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

吉林大学第二医院伦理委员会

Name of the ethic committee:

The Ethics Committee of the second hospital of Jilin University

伦理委员会批准日期:

Date of approved by ethic committee:

2023-08-01 00:00:00

伦理委员会联系人:

延正红

Contact Name of the ethic committee:

Yan Zhenghong

伦理委员会联系地址:

吉林省长春市南关区亚泰大街4026号

Contact Address of the ethic committee:

No. 4026 Yatai Street, Nanguan District, Changchun, Jilin, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 431 8113 6334

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

吉林大学第二医院

Primary sponsor:

The second hospital of Jilin University

研究实施负责(组长)单位地址:

中国吉林省长春市南关区自强街218号

Primary sponsor's address:

218 Ziqiang Street, Nanguan District, Changchun, Jilin, China.

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

长春

市(区县):

Country:

China

Province:

Changchun

City:

单位(医院):

吉林大学第二医院

具体地址:

吉林省长春市南关区亚泰大街4026号

Institution
hospital:

The second hospital of Jilin University

Address:

No. 4026 Yatai Street, Nanguan District, Changchun, Jilin, China

经费或物资来源:

吉林省科学技术厅

Source(s) of funding:

Jilin Provincial Science & Technology Department, China

研究疾病:

视力下降,双眼视觉异常  

Target disease:

Vision loss, binocular vision abnormalities

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

研究不同类型诱导性视力下降对立体视觉检查的影响  

Objectives of Study:

To study the effects of different types of induced vision loss on stereopsis examination

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

无系统性疾病,能够配合检查的成年人。本人或其监护人能够完成基本信息填写;能够和愿意签署知情同意书;每只眼睛的VA不低于0 LogMAR,苍蝇立体视锐度测试(美国伊利诺斯州视力评估公司) 立体视敏度不低于40″。

Inclusion criteria

Adults who have no systemic diseases and can cooperate with the examination. Subjects or their guardian can complete the basic information, able and willing to sign the informed consent form; the VA of each eye is not less than 0 LogMAR, and the stereo acuity test of flies (Illinois Vision Evaluation Company, USA) stereo acuity is not Below 40″.

排除标准:

无法配合眼科检查者

Exclusion criteria:

Unable to cooperate with the eye examination

研究实施时间:

Study execute time:

From 2023-08-11 00:00:00 To 2024-08-11 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-08-11 00:00:00 To 2024-08-11 00:00:00

干预措施:

Interventions:

组别:

视力下降组

样本量:

100

Group:

vision loss group

Sample size:

干预措施:

干预措施代码:

Intervention:

NA

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

长春 

市(区县):

 

Country:

China

Province:

Changhcun

City:

单位(医院):

吉林大学第二医院 

单位级别:

三甲 

Institution
hospital:

The second hospital of Jilin University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

视锐度

指标类型:

主要指标

Outcome:

vision acuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

立体视锐度

指标类型:

主要指标

Outcome:

stereo acuity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

屈光度

指标类型:

主要指标

Outcome:

diopter

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

NA

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

临床试验公共管理平台http://www.medresman.org.cn/login.aspx

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

ResMan,http://www.medresman.org.cn/login.aspx

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

CRFbu

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-08-11 16:47:15